FDA Approved: DIOVAN HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approves a supplemental application for Diovan HCT (valsartan/hydrochlorothiazide) submitted by Novartis, updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Diovan HCT (valsartan/hydrochlorothiazide)

Snippet

SUPPL AP for DIOVAN HCT (VALSARTAN AND HYDROCHLOROTHIAZIDE)